Pancreatic cancer drug-sensitivity predicted by synergy of p53-Activator Wnt Inhibitor-2 (PAWI-2) and protein biomarker expression [0.03%]
通过p53激活剂Wnt抑制剂-2 (PAWI-2)和蛋白质生物标志物表达的协同作用预测胰腺癌药物敏感性
Jiongjia Cheng,John R Cashman
Jiongjia Cheng
Today, pancreatic cancer (PC) is a major health problem in the United States. It remains a challenge to develop efficacious clinically useful PC therapies. New avenues, based on translational approaches and innovative validated biomarkers c...
Mitogen-activated protein kinases are involved in cucurbitacin D-induced antitumor effects on adult T-cell leukemia cells [0.03%]
葫芦素D诱导的成人T淋巴细胞白血病细胞的抗肿瘤效应涉及丝裂原激活的蛋白激酶路径
Duo Wang,Mengyue Shen,Noriaki Kitamura et al.
Duo Wang et al.
Adult T cell leukemia (ATL) is an aggressive and malignant blood disease. We previously reported that steroid-structured cucurbitacin D (CuD) induces apoptosis in ATL cells. In this study, we investigated the effects of mitogen-activated pr...
Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC) [0.03%]
pegilodecakin与5-FU / LV和奥沙利铂(FOLFOX)对胰腺导管腺癌(PDAC)的免疫反应和肿瘤反应
J Randolph Hecht,Kyriakos P Papadopoulos,Gerald S Falchook et al.
J Randolph Hecht et al.
Background Treatment options for pancreatic ductal adenocarcinoma (PDAC) are limited and checkpoint blockade inhibitors have been disappointing in this disease. Pegilodecakin has demonstrated single agent anti-tumor activity in immune-sensi...
Correction to: Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer [0.03%]
校正：一期新型口服PI3K / mTOR双重抑制剂LY3023414癌症患者的剂量爬坡研究
Shunsuke Kondo,Masaomi Tajimi,Tomohiko Funai et al.
Shunsuke Kondo et al.
The article Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer, written by Shunsuke Kondo, Masaomi Tajimi, Tomohiko Funai, Koichi Inoue, Hiroya Asou, Vinay Kumar Ranka, Volker Wacheck,...
Published Erratum
Investigational new drugs. 2020 Dec;38(6):1846. DOI:10.1007/s10637-020-00981-8 2020
The anti-malaria agent artesunate exhibits cytotoxic effects in primary effusion lymphoma [0.03%]
抗疟疾药青蒿琥酯对浆膜腔液淋巴瘤具有细胞毒性作用
Chie Ishikawa,Naoki Mori
Chie Ishikawa
Primary effusion lymphoma (PEL), caused by Kaposi's sarcoma-associated herpesvirus (KSHV), presents as a lymphomatous effusion in body cavities and has a poor prognosis. The anti-malaria drug, artesunate, possesses anti-neoplastic potential...
Novel [l,2,4]triazolo[3,4-a]isoquinoline chalcones as new chemotherapeutic agents: Block IAP tyrosine kinase domain and induce both intrinsic and extrinsic pathways of apoptosis [0.03%]
新型[l,2,4]三氮唑[3,4-a]异喹啉查尔酮作为新的化疗药物：阻断IAP酪氨酸激酶结构域并诱导细胞凋亡的内在和外在途径
Magda F Mohamed,Farid M Sroor,Nada S Ibrahim et al.
Magda F Mohamed et al.
Two novel chemotherapeutic chalcones were synthesized and their structures were confirmed by different spectral tools. Theoretical studies such as molecular modeling were done to detect the mechanism of action of these compounds. In vitro c...
Serum concentration of the CKD4/6 inhibitor abemaciclib, but not of creatinine, strongly predicts hematological adverse events in patients with breast cancer: a preliminary report [0.03%]
乳腺癌患者中，CKD4/6抑制剂abemaciclib的血清浓度而非肌酐浓度强烈预测血液学不良事件：初步报告
Akimitsu Maeda,Kei Irie,Naoya Hashimoto et al.
Akimitsu Maeda et al.
Purpose The CKD4/6 inhibitor abemaciclib is related to adverse events such as hematological toxicity and increase in serum creatinine levels associated with abemaciclib pharmacokinetics. Increase in serum creatinine levels is considered a r...
Observational Study
Investigational new drugs. 2021 Feb;39(1):272-277. DOI:10.1007/s10637-020-00994-3 2021
Atorvastatin in combination with radiotherapy and temozolomide for glioblastoma: a prospective phase II study [0.03%]
阿托伐他汀联合放疗和替莫唑胺治疗胶质母细胞瘤的前瞻性二期研究
Abdullah K Altwairgi,Waleed A Alghareeb,Fouad H AlNajjar et al.
Abdullah K Altwairgi et al.
Glioblastoma is a fast-growing primary brain tumor observed in adults with the worst prognosis. Preclinical studies have demonstrated the encouraging anticancer activity of statins. This study evaluated the efficacy of atorvastatin in combi...
Effects of zinc porphyrin and zinc phthalocyanine derivatives in photodynamic anticancer therapy under different partial pressures of oxygen in vitro [0.03%]
不同氧分压下锌卟啉和锌菁在体外光动力抗癌疗法中的效果研究
Martin Pola,Hana Kolarova,Jiri Ruzicka et al.
Martin Pola et al.
Photodynamic therapy (PDT) is gradually becoming an alternative method in the treatment of several diseases. Here, we investigated the role of oxygen in photodynamically treated cervical cancer cells (HeLa). The effect of PDT on HeLa cells ...
Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2-positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study) [0.03%]
埃里布林、帕妥珠单抗和曲妥珠单抗联合治疗人表皮生长因子受体2阳性晚期或转移性乳腺癌的疗效：一项多中心、单臂、II期研究（JBCRG-M03 研究）
Toshinari Yamashita,Hidetoshi Kawaguchi,Norikazu Masuda et al.
Toshinari Yamashita et al.
Purpose To date, it is not clear which anticancer agent is useful in combination with trastuzumab and pertuzumab As the first and second selective regimens for advanced or metastatic breast cancer (AMBC), this multicenter, open-label, phase...